PURPOSE Patients with newly diagnosed multiple myeloma (NDMM) show heterogeneous
outcomes, and approximately 60% of them are at intermediate-risk according to the Revised …

Multiple myeloma (MM) is a hematological malignancy characterized by clonal proliferation
of plasma cells. Although therapeutic advances have been made to improve clinical …

In multiple myeloma spatial differences in the subclonal architecture, molecular signatures
and composition of the microenvironment remain poorly characterized. To address this …

PURPOSE The multicenter OPTIMUM (MUKnine) phase II trial investigated daratumumab,
low-dose cyclophosphamide, lenalidomide, bortezomib, and dexamethasone (Dara-CVRd) …

Extra copies of chromosome 1q21 (+ 1q: gain= 3 copies, amp>= 4 copies) are associated
with worse outcomes in multiple myeloma (MM). This systematic review assesses the current …

Mass spectrometry (MS) is a promising tool for monitoring monoclonal protein in plasma cell
dyscrasias. We included 480 transplant-eligible newly-diagnosed multiple myeloma (MM) …

Cytogenetic abnormalities (CAs) are known to be the preponderant prognostic factor in
multiple myeloma. Our team has recently developed a prognostic score based on 6 CAs …

Background The prognostic value of additional copies of chromosome 1q (1q
gain/amplification [amp]) in multiple myeloma (MM) remains controversial. In the meantime …

Prediction of individual patient benefit from lenalidomide (Len) maintenance after
autologous stem cell transplant (ASCT) remains challenging. Here, we investigated …

Objectives In multiple myeloma and its precursor stages, plasma cell infiltration (PCI) and
cytogenetic aberrations are important for staging, risk stratification, and response …